IO Biotech announces first patient dosed in Phase 2 trial of IO102-IO103

IO Biotech announced that the first patient has been dosed in its Phase 2 trial studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the head and neck before and after surgery with curative intent. “We continue to see promising data and a favorable safety profile supporting use of our lead investigational therapeutic cancer vaccine candidate, IO102-IO103, combined with PD-1 inhibitors to treat various types of cancer, including melanoma, lung cancer and head and neck cancer,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “In patients with advanced melanoma, the activity and tolerability profile of IO102-IO103 and a PD-1 inhibitor has been demonstrated in the Phase 1/2 trial and we are now conducting a pivotal Phase 3 trial in patients with advanced melanoma, with enrollment completed in that study and an interim analysis planned in 2024. We are embarking on this neoadjuvant/adjuvant trial with the goal of also helping patients in earlier disease settings.”